Clinical Trials
10 trialsNCT03194893 2026-05-20
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT00390325 2024-02-06
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03780517 2023-10-30
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Boston Pharmaceuticals
Phase 1 Completed
NCT00514046 2020-12-22
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03154086 2019-08-09
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
GlaxoSmithKline
Phase 1 Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00325104 2017-07-02
Cinacalcet to Treat Familial Primary Hyperparathyroidism
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02727283 2017-05-08
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GlaxoSmithKline
Phase 1 Completed